Roche"s Child Arthritis Drug"s New Formulation Gets FDA Nod

REUTERS/Tobias Schwarz At least six coronavirus patients have been enrolled in a late-stage clinical trial testing the arthriti.....»»

Reuters President Donald Trump has repeatedly touted two drugs — chloroquine and hydroxychloroquine—as potential treatments for the new coronavirus.  The drug i.....»»

Last week, Mesoblast Limited (NASDAQ: MESO) was plugging away at therapies for heart failure, chronic back pain and rheumatoid arthritis. This week, it’s tackling the pandemic. read more.....»»

Biotech giant Genentech Inc. is working with federal agencies to start a late-stage clinical trial in early April of its already-approved rheumatoid arthritis drug Actemra against the virus that causes COVID-19. The South San Francisco company said th.....»»

"This could in a very short time give hope to the most critical people," Regeneron Chief Scientific Officer Dr. George Yancopoulos told CNBC......»»

The U.S. Food and Drug Administration (FDA) .....»»

A shortage of the chemotherapy drug vincristine, which is essential to the treatment of most pediatric cancers, has caused tremendous worry for families who might rely on the drug for their child's treatment. With t.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

AbbVie Inc on Friday forecast 2020 earnings above Wall Street estimates as the drugmaker expects growth to be powered by its new treatments for psoriasis and rheumatoid arthritis at a time when sales of its blockbuster drug Humira slow......»»

Vivus shares jumped on Wednesday after the company announced a crucial FDA for its supplemental New Drug Application for an improved formulation of Pancreaze......»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) 0 read more.....»»

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States......»»

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) 0 read more.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) 0 read more.....»»

One of the leading Cambridge biotechs hoping to treat diseases by silencing the underlying genetic cause has signed a billion-dollar deal to develop a hepatitis B treatment.  Drug giant Roche will pay $200 million upfront and up to $1.47 billion i.....»»

Pfizer Inc posted third-quarter profit well above analysts' estimates on higher sales of cancer drug Ibrance and arthritis medicine Xeljanz, encouraging the largest U.S. drugmaker to lift its earnings forecast for the year......»»

A Philadelphia jury on Tuesday ordered Johnson & Johnson to pay $8 billion in damages to a Maryland man who said his use of J&J’s antipsychotic Risperdal as a child caused enlarged breasts and the company failed to properly warn of this risk......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) read more.....»»

The U.S. Food and Drug Administration has approved AbbVie Inc's Rinvoq, a JAK kinase inhibitor, to treat moderate-to-severe rheumatoid arthritis in adults for whom methotrexate.....»»